Preventive and/or therapeutic agent for chronic cerebral circulatory failure

A technology of cerebral circulation and therapeutic agents, applied in the direction of organic active ingredients, active ingredients of heterocyclic compounds, medical preparations containing active ingredients, etc., can solve the problems of not disclosing effective or improving and increasing cerebral blood flow, etc., to improve cerebral blood flow. Circulatory metabolism, prevention or treatment of chronic cerebral circulatory insufficiency

Inactive Publication Date: 2007-02-14
MITSUBISHI TANABE PHARMA CORP
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, it has not been disclosed that the aminopropoxy bibenzyls are effective for chronic cerebral circulatory insufficiency or improve brain waves, thereby increasing cerebral blood flow

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preventive and/or therapeutic agent for chronic cerebral circulatory failure
  • Preventive and/or therapeutic agent for chronic cerebral circulatory failure
  • Preventive and/or therapeutic agent for chronic cerebral circulatory failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] (method)

[0060] 74 patients (40 males, 34 females) (Table-2) with peripheral circulatory insufficiency aged 60 or over were divided into two groups, and 300 mg / day of ticlopidine hydrochloride was administered to the ticlopidine group (43 patients) , 300 mg / day of sarcogrelate hydrochloride was administered to the sarcogrelate group (31 persons) for two years. There was no significant difference in the average age, male to female ratio, and average blood pressure between the ticlopidine group and the sarcogrelate group.

[0061] 〔table 3〕

[0062] Sagrelate group

Ticlopidine group

male / female (person)

17 / 14

23 / 20

age)

71.6±6.4

72.6±5.6

scope

(60～83)

(60～84)

60 years old or above

12 people (38.7%)

11 people (25.6%)

70 years or older

16 people (51.6%)

27 (62.8%)

80 years or older

3 people (9.7%)

5 people (11.6%)

Average blood pressure (mmHg)

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An ameliorant for cerebral circulatory metabolism or a preventive and/or therapeutic agent for chronic cerebral circulatory failures, characterized by containing any of an aminoalkoxybibenzil compound represented by the following general formula (1), a pharmaceutically acceptable salt thereof, and a hydrate or solvate of either.

Description

technical field [0001] The present invention relates to a preventive and / or therapeutic agent for chronic cerebral circulatory insufficiency, and an agent for improving cerebral circulation metabolism. Background technique [0002] Chronic cerebral circulatory insufficiency is a diagnostic name given to a disease in which subjective symptoms such as headache and dizziness fluctuate due to cerebral circulatory disturbance, but no organic disease suggesting vascularity is found in both clinical symptoms and imaging diagnosis. Lesions, and a disease that does not belong to the category of transient ischemic attack. Cerebral circulation improving agents (hereinafter also referred to as "cerebral circulation metabolism improving agents") are considered to be effective for subjective symptoms such as headache and dizziness (Non-Patent Document 1). [0003] In addition, although the long-term prediction of chronic cerebral insufficiency is not clear at present, if the onset of cer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/225A61K31/138A61K31/33A61P9/00
CPCA61K31/138A61K31/33A61K31/225A61P9/00A61P9/10A61K31/21
Inventor 岩隈裕明
Owner MITSUBISHI TANABE PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap